natgillin/translations-raw huggingface dataset:
Calves, Pigs, ChickensBroilers (not producing eggs for human consumption) 
Tilosina 20% Pagnini teleta, prašiči, pitovni piščanci (ki ne proizvajajo jajc za prehrano ljudi)
Swine, chicken 
prašiči, perutnina
Pharmasin 250 mg/g премикс за медикаментозен фураж за свине, бройлери и пилета, отглеждани за носачки 
Pharmasin 250 mg/g премикс за медикаментозен фураж за свине, бройлери и пилета, отглеждани за носачки prašiči, pitovni piščanci in jarkice
Pigs, chicken, turkeys 
prašiči, piščanci, purani
Pharmasin 1000 mg/g granules for use in drinking water for pigs, chickens, turkeys and calves 
Pharmasin 1000 mg/g granules for use in drinking water for pigs, chickens, turkeys and calves govedo, prašiči, piščanci, purani
Delete, where applicable, any references to swine dysentery caused by Brachyspira hyodysenteriae. 
Če je primerno, izbrišite morebitno referenco na prašičjo dizenterijo, ki jo povzroča Brachyspira hyodysenteriae.
Tilosina 20% Vetoquinol 
Tilosina 20% Vetoquinol prašiči, piščanci
PHARMASIN 20 G/KG PREMELANGE M EDICAMENTEUX VOLAILLE PORCS 
PHARMASIN 20 G/KG PREMELANGE
TRELACON G 50 PREMEZCLA Tylosin 
TRELACON G 50 PREMEZCLA Tylosin prašiči, perutnina
TILOSINA 100 GANADEXIL 
TILOSINA 100 GANADEXIL Tylosin tartarate
Pharmasin 100 mg/g Premix for medicated feeding stuff for pigs, broilers and pullets 
Pharmasin 100 mg/g Premix for Medicated Feeding Stuff for Pigs, Broilers and Pullets prašiči perutnina
Pharmasin 250 mg/g Premix for Medicated Feeding Stuff for Pigs, Broilers and Pullets 
Pharmasin 250 mg/g Premix for Medicated Feeding Stuff for Pigs, Broilers and Pullets prašiči perutnina
1.1 g of granules contains 1 g of tylosin 
1.1 g of granules contains 1 g of tylosin teleta, prašiči, piščanci, purani
Poultry, pig 
Tylmasin perutnina, prašiči
Klato lan feed 
Klato lan feed prašiči piščanci
Pigs, chicken (broiler), turkeys 
prašiči, piščanci (pitovni), purani
Calves, pigs, poultry 
teleta, prašiči, piščanci, purani
Calves Pigs Chicken Turkey 
teleta prašiči piščanci purani
Pigs, chickens, turkeys and calves 
prašiči, piščanci, purani in teleta
Cattle Chickens Pigs 
Klato lan prašiči piščanci
, Karlsson et al. (1999) 
, Karlsson in sod.
Germany Huvepharma NV Uitbreidingstraat 80 
Romunija Huvepharma NV Uitbreidingstraat 80
Lithuania Huvepharma NV Uitbreidingstraat 80 
Madžarska Huvepharma NV Uitbreidingstraat 80
Pigs 
Ciper
TYLAN 100 mg/g premix 
PHARMASIN 100 MG/G PREMEZCLA
Chickens (broilers, pullets, laying hens), turkeys, pigs, calves 
PURTYL, geriamieji milteliai piščanci, purani, svinje in teleta
Cattle, chickens, turkeys and pigs 
1 g/g govedo, piščanci, purani in prašiči
Oral solution Calves, chickens, pigs 
peroralna raztopina teleta, piščanci, prašiči
108.18 g/110 g Powder for oral solution 
108.18 g/110 g prašek za peroralno raztopino piščanci, purani in prašiči
Poultry, swine, calves 
prašiči, pitovni piščanci, jarkice
This summary was last updated in 12-2012. 
Povzetek je bil nazadnje posodobljen 12-2012.
The patches should not be cut into pieces. 
Ne sme se jih rezati na manjše koščke.
The European Commission granted a marketing authorisation valid throughout the European Union for Prometax on 4 December 1998. 
Evropska komisija je dovoljenje za promet z zdravilom Prometax, veljavno po vsej Evropski uniji, odobrila dne 4. decembra 1998.
The starting dose is 1.5 mg twice a day. 
Začetni odmerek je 1,5 mg dvakrat na dan.
EPAR summary for the public rivastigmine 
Povzetek EPAR za javnost rivastigmin
The patches can be worn during bathing and hot weather. 
Obliže je mogoče nositi tudi med kopanjem in v toplem vremenu.
The main measures of effectiveness were the change in symptoms in two main areas: cognitive (the ability to think, learn and remember) and global (a combination of several areas including general function, cognitive symptoms, behaviour and the ability to carry out everyday activities). 
Glavno merilo učinkovitosti je bila sprememba simptomov na dveh glavnih področjih: kognitivnem (sposobnost mišljenja, učenja in pomnjenja) in celostnem (kombinacija več področij, vključno s splošno funkcijo, kognitivnimi simptomi, vedenjem in sposobnostjo izvajanja vsakodnevnih dejavnosti).
However, following a re-examination of this opinion, the Committee concluded that the medicine's modest effectiveness could also be of benefit to some of these patients. 
Vendar pa je po ponovni presoji svojega mnenja zaključil, da lahko skromna učinkovitost zdravila koristi nekaterim bolnikom.
The full EPAR for Prometax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Prometax je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The capsules have been studied in 2,126 patients in three main studies, and the transdermal patches in one main study involving 1,195 patients. 
Kapsule so proučevali pri 2 126 bolnikih v treh glavnih študijah, transdermalne obliže pa v eni glavni študiji, ki je vključevala 1 195 bolnikov.
The patches are applied to clean, dry, hairless, intact skin on the back, upper arm or chest, and are replaced every 24 hours. 
Obliže je treba prilepiti na čisto, suho, nepoškodovano in neporaščeno kožo na hrbtu, nadlakti ali prsih in zamenjati vsakih 24 ur.
This is a summary of the European public assessment report (EPAR) for Prometax. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Prometax.
Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects. 
Zdravljenje je treba nadaljevati, dokler je zdravilo učinkovito, vendar se lahko odmerek zmanjša ali zdravljenje prekine, če se pri bolniku pojavijo neželeni učinki.
Other information about Prometax 
Druge informacije o zdravilu Prometax
Prometax capsules or oral solution should be given twice a day, with morning and evening meals. 
Kapsule ali peroralna raztopina zdravila Prometax se dajejo dvakrat na dan ob jutranjem in večernem obroku.
The Committee initially concluded that for the treatment of dementia due to Parkinson's disease, Prometax's benefits did not outweigh its risks. 
Odbor je prvotno sklenil, da za zdravljenje demence, ki je posledica Parkinsonove bolezni, koristi zdravila Prometax ne odtehtajo njegovih tveganj.
This was compared with an increase of 2.6 points from 22.5 in the patients taking placebo. 
Rezultat so primerjali s povečanjem za 2,6 točke od 22,5 pri bolnikih, ki so jemali placebo.
The CHMP concluded that Prometax has a modest effectiveness in treating the symptoms of Alzheimer's dementia, although this does reflect an important benefit in some patients. 
CHMP je zaključil, da ima zdravilo Prometax pri zdravljenju simptomov Alzheimerjeve demence skromen učinek, čeprav ta pomeni pomembno korist za nekatere bolnike.
What measures are being taken to ensure the safe use of Prometax? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Prometax?
Overall, the most common side effects (seen in more than 1 patient in 10) include nausea (feeling sick) and vomiting, particularly during the phase when the dose of Prometax is being increased. 
Na splošno sta med najpogostejšimi neželenimi učinki (opaženimi pri več kot 1 bolniku od 10) navzeja (slabost) in bruhanje, zlasti v obdobju povečevanja odmerka zdravila Prometax.
All of the studies lasted six months and compared the effects of Prometax with those of placebo (a dummy treatment). 
Vse študije so trajale šest mesecev, v njih pa so primerjali učinke zdravila Prometax z učinki placeba (zdravila brez zdravilne učinkovine).
Prometax is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. 
Zdravilo Prometax se uporablja za zdravljenje bolnikov z blago do zmerno hudo Alzheimerjevo demenco, napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). 
Pri bolnikih z Alzheimerjevo demenco ali demenco zaradi Parkinsonove bolezni v možganih odmirajo določene živčne celice, zaradi česar se znižajo ravni živčnega prenašalca acetilholina (snovi, ki omogoča medsebojno komunikacijo med živčnimi celicami).
Prometax must also not be used in patients who are suspected to have had in the past a severe allergic reaction called ‘allergic contact dermatitis' to Prometax patch. 
Prav tako ga ne smejo uporabljati bolniki, pri katerih obstaja sum, da so v preteklosti doživeli hudo alergijsko reakcijo, imenovano „alergijski kontaktni dermatitis“, na obliže zdravila Prometax.
Treatment should only be started if a caregiver is available who will regularly give and monitor the use of Prometax by the patient. 
Zdravljenje se lahko začne samo, če je na voljo negovalec, ki bo redno dajal zdravilo in spremljal uporabo zdravila Prometax pri bolniku.
Treatment with Prometax should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease. 
Zdravljenje z zdravilom Prometax mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni ali demence pri bolnikih s Parkinsonovo boleznijo.
For more information about treatment with Prometax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Prometax preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Therefore, the Committee decided that Prometax's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Zato je zaključil, da so koristi zdravila Prometax večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prometax. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Prometax, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Prometax capsules have also been studied in 541 patients with dementia due to Parkinson's disease. 
Kapsule zdravila Prometax so proučevali tudi pri 541 bolnikih z demenco kot posledico Parkinsonove bolezni.
What benefit has Prometax shown during the studies? 
Kakšne koristi je zdravilo Prometax izkazalo med študijami?
Prometax must not be used in people who are hypersensitive (allergic) to rivastigmine, other carbamate derivatives or any of the other ingredients. 
Zdravila Prometax ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) rivastigmin, druge derivate karbamata ali katero koli drugo sestavino zdravila.
An additional study in 27 patients was used to show that Prometax capsules and oral solution produced similar levels of the active substance in the blood. 
Z dodatno študijo s 27 bolniki so dokazali, da kapsule in peroralna raztopina zdravila Prometax dosegajo podobne ravni zdravilne učinkovine v krvi.
The Prometax transdermal patches were also more effective than placebo in preventing dementia from getting worse. 
Transdermalni obliži Prometax so bili ravno tako učinkovitejši od placeba pri preprečevanju poslabšanja demence.
They should not be placed on irritated or red skin, on the thigh or abdomen (tummy), or in places where they will be rubbed by tight clothing. 
Ne smejo se prilepiti na vzdraženo ali pordelo kožo, na stegno ali trebuh ali na predele, kjer bi se drgnili ob tesna oblačila.
The global symptom score also improved more in the patients taking Prometax. 
Tudi rezultat celostne ocene simptomov je bil boljši pri bolnikih, ki so jemali zdravilo Prometax.
It is available as capsules (1.5, 3, 4.5 and 6 mg), as an oral solution (2 mg/ml), and as transdermal patches, which release either 4.6 , 9.5 or 13.3 mg rivastigmine across the skin over 24 hours. 
Na voljo je v obliki kapsul (1,5 mg, 3 mg, 4,5 mg in 6 mg), kot peroralna raztopina (2 mg/ml) in transdermalni obliž, ki v 24 urah skozi kožo sprosti 4,6 mg, 9,5 mg ali 13,3 mg rivastigmina.
Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. 
Rivastigmin deluje tako, da zavira encima, ki razgrajujeta acetilholin: acetilholinesterazo in butirilholinesterazo.
The company that makes Prometax must ensure that all doctors who intend to prescribe Prometax transdermal patch receive an information pack containing instructions to be given to patients and caregivers on how to use the patch safely as well as a reminder card for patients and caregivers that contains key information on how to use the patch and allows them to record the application and removal of patches. 
Družba, ki proizvaja zdravilo Prometax mora zagotoviti, da vsi zdravniki, ki bodo predpisovali transdermalne obliže zdravila Prometax v odmerku 13,3 mg/24 ur, prejmejo informacijsko gradivo z navodili za varno uporabo obližev, ki jih je treba posredovati bolnikom in negovalcem, ter opozorilno kartico za bolnike in negovalce, ki vsebuje ključne informacije o načinu uporabe obližev in beležko za vodenje evidence o namestitvi in odstranitvi obližev.
The capsules and oral solution can also be used to treat mild to moderately severe dementia in patients with Parkinson's disease. 
Kapsule in peroralna raztopina se lahko uporabljajo tudi za zdravljenje blage do zmerno hude demence pri bolnikih s Parkinsonovo boleznijo.
Prometax was more effective than placebo at controlling symptoms. 
Zdravilo Prometax je bilo pri obvladovanju simptomov učinkovitejše od placeba.
Prometax is a medicine containing the active substance rivastigmine. 
Prometax je zdravilo, ki vsebuje zdravilno učinkovino rivastigmin.
The types of side effects seen with Prometax depend on the type of dementia it is being used to treat and whether the capsules, oral solution or transdermal patches are used. 
Vrste neželenih učinkov, opaženih pri zdravilu Prometax, so odvisne od vrste demence, ki se zdravi, in od tega, ali se uporabljajo kapsule, peroralna raztopina ali transdermalni obliži.
By blocking these enzymes, Prometax allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia associated with Parkinson's disease. 
Zdravilo Prometax z zaviranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi Alzheimerjeve demence in demence zaradi Parkinsonove bolezni ublažijo.
For the transdermal patch application site reactions are the most commonly seen side effects. 
Pri uporabi transdermalnega obliža so najpogostejši neželeni učinki reakcije na mestu uporabe obliža.
Prometax has been studied in mild to moderately severe Alzheimer's disease. 
Zdravilo Prometax so proučevali pri blagi do zmerno hudi Alzheimerjevi bolezni.
In the three studies of Prometax capsules in patients with Alzheimer's dementia, patients taking doses of Prometax between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance. 
V treh študijah zdravila Prometax pri bolnikih z Alzheimerjevo demenco je bilo pri tistih, ki so jemali od 6- do 9miligramske odmerke zdravila Prometax, opaziti povprečno povečanje kognitivnih simptomov za 0,2 točke od izhodiščne vrednosti 22,9 točke na začetku študije, pri čemer nižji rezultat pomeni boljšo učinkovitost.
What is the risk associated with Prometax? 
Kakšna tveganja so povezana z zdravilom Prometax?
The patients with dementia due to Parkinson's disease taking Prometax capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points. 
Pri bolnikih z demenco zaradi Parkinsonove bolezni, ki so jemali kapsule zdravila Prometax, je bilo opaziti izboljšanje kognitivnih simptomov za 2,1 točke, v primerjavi s poslabšanjem za 0,7 točke pri tistih, ki so jemali placebo, od izhodiščne vrednosti približno 24 točk.
The active substance in Prometax, rivastigmine, is an antidementia medicine. 
Zdravilna učinkovina zdravila Prometax, rivastigmin, je zdravilo za zdravljenje demence.
For the global score, patients taking Prometax capsules had in increase in symptoms of 4.1 points, compared with 4.4 in those taking placebo. 
Kar zadeva rezultat celostne ocene simptomov, je pri bolnikih, ki so jemali kapsule zdravila Prometax, prišlo do povečanja simptomov za 4,1 točke v primerjavi s 4,4 točke pri tistih, ki so jemali placebo.
Patients can be switched from the capsules or oral solution to the patches. 
Bolniki lahko s kapsul ali peroralne raztopine preidejo na obliže.
Why has Prometax been approved? 
Zakaj je bilo zdravilo Prometax odobreno?
For the full list of all side effects reported with Prometax, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Prometax, glejte navodilo za uporabo.
See the summary of product characteristics (also part of the EPAR) for detailed information. 
Za več informacij glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
If the transdermal patches are used, the 4.6 mg per 24 hours patch should be used first, with the dose increased to the 9.5 mg/24 h patch after at least four weeks if the lower dose is well tolerated. 
Če se uporabljajo transdermalni obliži, je treba najprej uporabiti obliž, ki v 24 urah sprosti 4,6 mg učinkovine, po najmanj štirih tednih pa je odmerek mogoče povečati na 9,5 mg v 24 urah, če bolnik nižji odmerek dobro prenaša.
The 9.5 mg/24 h patch should be used for as long as the patient benefits from it. After six months of treatment with 9.5 mg/24 hours, the doctor may increase the dose to 13.3 mg/24 hours if the patient's condition has worsened. 
Po šestih mesecih zdravljenja z obližem, ki vsebuje odmerek 9,5 mg/24 ur, lahko zdravnik odmerke poviša na 13,3 mg/24 ur, če se bolnikovo stanje poslabša.
In patients who tolerate this dose, it can be increased in 1.5 mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day. 
Pri bolnikih, ki prenašajo navedeni odmerek, se lahko ta postopoma povečuje za 1,5 mg, vendar ne pogosteje kot vsaka dva tedna, dokler se ne doseže stalni odmerek 3 do 6 mg dvakrat na dan. Za dosego največje učinkovitosti se uporabi največji odmerek, ki ga bolnik še prenaša, vendar ta ne sme preseči 6 mg dvakrat na dan.
How does Prometax work? 
Kako zdravilo Prometax deluje?
How has Prometax been studied? 
Kako je bilo zdravilo Prometax raziskano?
What is Prometax? 
Kaj je zdravilo Prometax?
What is Prometax used for? 
Za kaj se zdravilo Prometax uporablja?
How is Prometax used? 
Kako se zdravilo Prometax uporablja?
After the starting dose, Amgevita is most often given every two weeks, but it may be given every week in certain situations. 
Po začetnem odmerku se zdravilo Amgevita najpogosteje daje vsaka dva tedna, vendar pa se v nekaterih okoliščinah lahko daje vsak teden.
This means that Amgevita is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU). 
To pomeni, da je podobno biološkemu zdravilu (t. i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
What measures are being taken to ensure the safe and effective use of Amgevita? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Amgevita?
The full EPAR for Amgevita can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Amgevita je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It is not intended to provide practical advice on how to use Amgevita. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
These packs will include information on the safety of the medicine and an alert card to be given to patients. 
To bo vsebovalo informacije o varnosti zdravila in opozorilno kartico za bolnike.
Other information about Amgevita 
Druge informacije o zdravilu Amgevita
This is a summary of the European public assessment report (EPAR) for Amgevita. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Amgevita.
What are the risks associated with Amgevita? 
Kakšna tveganja so povezana z zdravilom Amgevita?
By attaching to TNF, adalimumab blocks its activity, thereby reducing inflammation and other symptoms of the diseases. 
Adalimumab z vezavo na TNF zavre njegovo delovanje in tako zmanjša vnetje in druge simptome bolezni.
After training, patients or their carers may inject Amgevita if their doctor considers it appropriate. 
Bolniki ali njihovi skrbniki lahko po opravljenem usposabljanju sami injicirajo zdravilo Amgevita, če zdravnik meni, da je to zanje primerno.
The medicine is available as a solution for injection under the skin in a pre-filled syringe or pen. 
Zdravilo je na voljo kot raztopina za injiciranje pod kožo v napolnjeni injekcijski brizgi ali peresniku.
Patients may be given other medicines during treatment with Amgevita, such as methotrexate or corticosteroids (other anti‑inflammatory medicines). 
Bolnikom se med zdravljenjem z zdravilom Amgevita lahko dajejo tudi druga zdravila, kot so metotreksat ali kortikosteroidi (druga protivnetna zdravila).
Amgevita is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments. 
Zdravilo Amgevita se večinoma uporablja pri odraslih, katerih bolezen je huda, zmerno huda ali se poslabšuje oziroma kadar bolnik ne more prejemati drugega zdravljenja.
The company that markets Amgevita must provide educational packs for doctors who will prescribe the medicine. 
Družba, ki trži zdravilo Amgevita, mora pripraviti izobraževalno gradivo za zdravnike, ki ga bodo predpisovali.
What benefits of Amgevita have been shown in studies? 
Kakšne koristi je zdravilo Amgevita izkazalo v študijah?
For detailed information on the use of Amgevita in all conditions, including when it can be used in children, see the summary of product characteristics (also part of the EPAR). 
Za več informacij o uporabi zdravila Amgevita pri vseh navedenih boleznih, vključno s tem, kdaj se lahko uporablja pri otrocih, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
The reference medicine for Amgevita is Humira. 
Referenčno zdravilo za zdravilo Amgevita je zdravilo Humira.
The dose depends on the condition to be treated and in children is usually calculated according to the child's weight and height. 
Odmerek je odvisen od bolezni, ki se zdravi, pri otrocih pa se odmerek običajno izračuna na podlagi telesne mase in višine otroka.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Amgevita have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Amgevita upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Amgevita is a medicine that acts on the immune system and is used to treat the following conditions: 
Zdravilo Amgevita učinkuje na imunski sistem in se uporablja za zdravljenje naslednjih bolezni: